197 related articles for article (PubMed ID: 24810715)
1. Chemical strategies for development of ATR inhibitors.
Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T
Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715
[TBL] [Abstract][Full Text] [Related]
2. The development of ataxia telangiectasia mutated kinase inhibitors.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM; Zou L
Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
[TBL] [Abstract][Full Text] [Related]
4. Targeting ATR in DNA damage response and cancer therapeutics.
Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ
Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268
[TBL] [Abstract][Full Text] [Related]
5. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
6. Targeting the S and G2 checkpoint to treat cancer.
Chen T; Stephens PA; Middleton FK; Curtin NJ
Drug Discov Today; 2012 Mar; 17(5-6):194-202. PubMed ID: 22192883
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
[TBL] [Abstract][Full Text] [Related]
9. ATR prohibits replication catastrophe by preventing global exhaustion of RPA.
Toledo LI; Altmeyer M; Rask MB; Lukas C; Larsen DH; Povlsen LK; Bekker-Jensen S; Mailand N; Bartek J; Lukas J
Cell; 2013 Nov; 155(5):1088-103. PubMed ID: 24267891
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
[TBL] [Abstract][Full Text] [Related]
11. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
12. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
13. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Gorecki L; Andrs M; Rezacova M; Korabecny J
Pharmacol Ther; 2020 Jun; 210():107518. PubMed ID: 32109490
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).
Ramachandran SA; Jadhavar PS; Singh MP; Sharma A; Bagle GN; Quinn KP; Wong PY; Protter AA; Rai R; Pham SM; Lindquist JN
Bioorg Med Chem Lett; 2017 Feb; 27(4):750-754. PubMed ID: 28131712
[TBL] [Abstract][Full Text] [Related]
15. Sulfoximines as ATR inhibitors: Analogs of VE-821.
Hendriks CMM; Hartkamp J; Wiezorek S; Steinkamp AD; Rossetti G; Lüscher B; Bolm C
Bioorg Med Chem Lett; 2017 Jun; 27(12):2659-2662. PubMed ID: 28479198
[TBL] [Abstract][Full Text] [Related]
16. Targeted cancer therapies based on the inhibition of DNA strand break repair.
O'Connor MJ; Martin NM; Smith GC
Oncogene; 2007 Dec; 26(56):7816-24. PubMed ID: 18066095
[TBL] [Abstract][Full Text] [Related]
17. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity.
Patel A; Seraia E; Ebner D; Ryan AJ
Int J Cancer; 2020 Sep; 147(5):1474-1484. PubMed ID: 32159854
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T
J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286
[TBL] [Abstract][Full Text] [Related]
19. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Blackford AN; Jackson SP
Mol Cell; 2017 Jun; 66(6):801-817. PubMed ID: 28622525
[TBL] [Abstract][Full Text] [Related]
20. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
Ashwell S; Zabludoff S
Clin Cancer Res; 2008 Jul; 14(13):4032-7. PubMed ID: 18593978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]